Acumen Pharmaceuticals (ABOS) Competitors $1.26 -0.01 (-0.79%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS vs. NBTX, RNAC, RCKT, CADL, AMRN, INBX, NGNE, IVA, FDMT, and AVIRShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Nanobiotix (NBTX), Cartesian Therapeutics (RNAC), Rocket Pharmaceuticals (RCKT), Candel Therapeutics (CADL), Amarin (AMRN), Inhibrx Biosciences (INBX), Neurogene (NGNE), Inventiva (IVA), 4D Molecular Therapeutics (FDMT), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. Its Competitors Nanobiotix Cartesian Therapeutics Rocket Pharmaceuticals Candel Therapeutics Amarin Inhibrx Biosciences Neurogene Inventiva 4D Molecular Therapeutics Atea Pharmaceuticals Nanobiotix (NASDAQ:NBTX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership. Do analysts recommend NBTX or ABOS? Nanobiotix presently has a consensus price target of $8.00, suggesting a potential downside of 0.31%. Acumen Pharmaceuticals has a consensus price target of $6.33, suggesting a potential upside of 402.65%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, NBTX or ABOS? Nanobiotix has higher earnings, but lower revenue than Acumen Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix-$11.61M-33.14-$73.73MN/AN/AAcumen PharmaceuticalsN/AN/A-$102.33M-$2.28-0.55 Does the media prefer NBTX or ABOS? In the previous week, Acumen Pharmaceuticals had 8 more articles in the media than Nanobiotix. MarketBeat recorded 10 mentions for Acumen Pharmaceuticals and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 1.87 beat Acumen Pharmaceuticals' score of 0.11 indicating that Nanobiotix is being referred to more favorably in the media. Company Overall Sentiment Nanobiotix Very Positive Acumen Pharmaceuticals Neutral Is NBTX or ABOS more profitable? Nanobiotix's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A Acumen Pharmaceuticals N/A -73.93%-57.71% Which has more volatility and risk, NBTX or ABOS? Nanobiotix has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Do institutionals & insiders hold more shares of NBTX or ABOS? 38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryAcumen Pharmaceuticals beats Nanobiotix on 7 of the 12 factors compared between the two stocks. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.02M$3.08B$5.57B$9.81BDividend YieldN/A2.27%4.62%4.12%P/E Ratio-0.5520.7329.8025.74Price / SalesN/A356.90460.01111.33Price / CashN/A42.0537.7558.93Price / Book0.427.608.496.01Net Income-$102.33M-$54.65M$3.25B$264.84M7 Day Performance-11.27%4.45%3.71%2.66%1 Month Performance-15.44%5.71%4.03%1.56%1 Year Performance-49.90%30.51%35.47%29.07% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals3.2488 of 5 stars$1.26-0.8%$6.33+402.6%-54.2%$76.02MN/A-0.5520Earnings ReportNBTXNanobiotix0.7601 of 5 stars$6.80flat$8.00+17.6%+65.6%$320.51M$39.18M0.00100Positive NewsGap UpHigh Trading VolumeRNACCartesian Therapeutics1.9505 of 5 stars$12.48+1.2%$40.00+220.5%-14.3%$320.02M$38.91M-0.2464Positive NewsEarnings ReportRCKTRocket Pharmaceuticals4.8722 of 5 stars$3.07+2.7%$17.87+482.0%-83.8%$319.29MN/A-1.17240Earnings ReportAnalyst ForecastAnalyst RevisionCADLCandel Therapeutics2.3697 of 5 stars$6.31+0.3%$22.00+248.7%+9.6%$315.15MN/A-4.7160News CoverageEarnings ReportAMRNAmarin0.5542 of 5 stars$15.38+1.5%$12.00-22.0%+22.5%$313.92M$228.61M-4.19360Positive NewsINBXInhibrx Biosciences2.0511 of 5 stars$21.80+0.9%N/A+108.6%$312.68M$200K0.19166News CoverageEarnings ReportShort Interest ↓NGNENeurogene2.3981 of 5 stars$21.72-0.3%$46.17+112.6%-38.2%$310.63M$925K-4.9990News CoverageEarnings ReportAnalyst RevisionIVAInventiva2.9554 of 5 stars$3.24+0.6%$10.40+221.0%+82.7%$308.03M$9.95M0.00100Gap DownHigh Trading VolumeFDMT4D Molecular Therapeutics2.3283 of 5 stars$5.24-18.4%$29.56+464.0%-55.4%$297.40M$40K-1.65120News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionAVIRAtea Pharmaceuticals2.0984 of 5 stars$3.53+1.7%$6.00+70.0%-4.4%$296.96MN/A-2.1470Earnings Report Related Companies and Tools Related Companies NBTX Competitors RNAC Competitors RCKT Competitors CADL Competitors AMRN Competitors INBX Competitors NGNE Competitors IVA Competitors FDMT Competitors AVIR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABOS) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access